The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis
Objective: The study aimed to evaluate the effect of sodium–glucose transporter 2 (SGLT-2) inhibitors on various parameters of exercise capacity and provide an evidence-based basis for type 2 diabetes mellitus (T2DM) combined with heart failure (HF) patients or HF patients without T2DM who use SGLT-...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Physiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2022.1081920/full |
| _version_ | 1797956509782507520 |
|---|---|
| author | Yong Peng Yong Peng Yong Peng Di Qin Yudi Wang Lian Xue YaXuan Qin Xin Xu |
| author_facet | Yong Peng Yong Peng Yong Peng Di Qin Yudi Wang Lian Xue YaXuan Qin Xin Xu |
| author_sort | Yong Peng |
| collection | DOAJ |
| description | Objective: The study aimed to evaluate the effect of sodium–glucose transporter 2 (SGLT-2) inhibitors on various parameters of exercise capacity and provide an evidence-based basis for type 2 diabetes mellitus (T2DM) combined with heart failure (HF) patients or HF patients without T2DM who use SGLT-2 inhibitors to improve cardiorespiratory fitness (CRF).Methods: According to the participant, intervention, comparison, and outcome (PICO) elements, the effects of SGLT-2 inhibitor administration on VO2 or VO2peak were researched in this study. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were calculated (random-effects model). Heterogeneity was assessed by the I2 test.Results: Six studies were included according to the eligibility criteria: four were RCTs, and two were non-RCTs. Compared with the control group, the merge results of RCTs showed that SGLT-2 inhibitors could significantly increase the VO2peak (WMD, 2.02 ml kg−1 min−1, 95% CI: 0.68–3.37, and p = 0.03; I2 = 0% and p = 0.40) and VAT (WMD, 1.57 ml kg−1 min−1, 95% CI: 0.06–3.07, and p = 0.04; I2 = 0% and p = 0.52) of the obese population, patients with T2DM, and chronic HF patients with or without T2DM. Subgroup analysis showed that SGLT-2 inhibitors improved the VO2peak in non-HF patients (WMD, 3.57 ml kg−1 min−1, 95% CI: 0.87–6.26, and p = 0.009; I2 = 4% and p = 0.31) more than in HF patients (WMD, 1.46 ml kg−1 min−1, 95% CI: −0.13–3.04, and p = 0.07; I2 = 0% and p = 0.81). Moreover, the merge of single-arm studies also indicated that empagliflozin could improve VO2peak (MD, 1.11 ml kg−1 min−1, 95% CI: 0.93–1.30, and p = 0.827, Δ p = 0.000 and I2 = 0%) of T2DM patients with chronic HF.Conclusion: Despite the limited number of studies and samples involved, the meta-analysis preliminarily demonstrated that SGLT-2 inhibitors could improve some parameters of exercise capacity (VO2peak, VAT) in chronic HF patients with or without T2DM and obese individuals, which had a positive effect on promoting cardiopulmonary fitness to help these populations improve their prognosis.Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/#recordDetails], identifier [CRD42020202788]. |
| first_indexed | 2024-04-10T23:49:59Z |
| format | Article |
| id | doaj.art-33d2ec8c9c844852a08758bd6289d2ef |
| institution | Directory Open Access Journal |
| issn | 1664-042X |
| language | English |
| last_indexed | 2024-04-10T23:49:59Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Physiology |
| spelling | doaj.art-33d2ec8c9c844852a08758bd6289d2ef2023-01-10T18:52:59ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2023-01-011310.3389/fphys.2022.10819201081920The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysisYong Peng0Yong Peng1Yong Peng2Di Qin3Yudi Wang4Lian Xue5YaXuan Qin6Xin Xu7School of Kinesiology, Shanghai University of Sport, Shanghai, ChinaJiangsu Collaborative Innovation Center for Sports and Health Project, Nanjing Sport Institute, Nanjing, Jiangsu, ChinaKey Laboratory of Human Sports Science for Jiangsu Province, Nanjing Sport Institute, Nanjing, Jiangsu, ChinaSchool of Sport Health, Nanjing Sport Institute, Nanjing, Jiangsu, ChinaSchool of Physical Education and Nursing, Chengdu College of Arts and Sciences, Chengdu, ChinaKey Laboratory of Human Sports Science for Jiangsu Province, Nanjing Sport Institute, Nanjing, Jiangsu, ChinaSchool of Sport Health, Nanjing Sport Institute, Nanjing, Jiangsu, ChinaSchool of Kinesiology, Shanghai University of Sport, Shanghai, ChinaObjective: The study aimed to evaluate the effect of sodium–glucose transporter 2 (SGLT-2) inhibitors on various parameters of exercise capacity and provide an evidence-based basis for type 2 diabetes mellitus (T2DM) combined with heart failure (HF) patients or HF patients without T2DM who use SGLT-2 inhibitors to improve cardiorespiratory fitness (CRF).Methods: According to the participant, intervention, comparison, and outcome (PICO) elements, the effects of SGLT-2 inhibitor administration on VO2 or VO2peak were researched in this study. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were calculated (random-effects model). Heterogeneity was assessed by the I2 test.Results: Six studies were included according to the eligibility criteria: four were RCTs, and two were non-RCTs. Compared with the control group, the merge results of RCTs showed that SGLT-2 inhibitors could significantly increase the VO2peak (WMD, 2.02 ml kg−1 min−1, 95% CI: 0.68–3.37, and p = 0.03; I2 = 0% and p = 0.40) and VAT (WMD, 1.57 ml kg−1 min−1, 95% CI: 0.06–3.07, and p = 0.04; I2 = 0% and p = 0.52) of the obese population, patients with T2DM, and chronic HF patients with or without T2DM. Subgroup analysis showed that SGLT-2 inhibitors improved the VO2peak in non-HF patients (WMD, 3.57 ml kg−1 min−1, 95% CI: 0.87–6.26, and p = 0.009; I2 = 4% and p = 0.31) more than in HF patients (WMD, 1.46 ml kg−1 min−1, 95% CI: −0.13–3.04, and p = 0.07; I2 = 0% and p = 0.81). Moreover, the merge of single-arm studies also indicated that empagliflozin could improve VO2peak (MD, 1.11 ml kg−1 min−1, 95% CI: 0.93–1.30, and p = 0.827, Δ p = 0.000 and I2 = 0%) of T2DM patients with chronic HF.Conclusion: Despite the limited number of studies and samples involved, the meta-analysis preliminarily demonstrated that SGLT-2 inhibitors could improve some parameters of exercise capacity (VO2peak, VAT) in chronic HF patients with or without T2DM and obese individuals, which had a positive effect on promoting cardiopulmonary fitness to help these populations improve their prognosis.Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/#recordDetails], identifier [CRD42020202788].https://www.frontiersin.org/articles/10.3389/fphys.2022.1081920/fullSGLT-2 inhibitorsexercise capacityT2DMheart failureVO2peak |
| spellingShingle | Yong Peng Yong Peng Yong Peng Di Qin Yudi Wang Lian Xue YaXuan Qin Xin Xu The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis Frontiers in Physiology SGLT-2 inhibitors exercise capacity T2DM heart failure VO2peak |
| title | The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis |
| title_full | The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis |
| title_fullStr | The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis |
| title_full_unstemmed | The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis |
| title_short | The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis |
| title_sort | effect of sglt 2 inhibitors on cardiorespiratory fitness capacity a systematic review and meta analysis |
| topic | SGLT-2 inhibitors exercise capacity T2DM heart failure VO2peak |
| url | https://www.frontiersin.org/articles/10.3389/fphys.2022.1081920/full |
| work_keys_str_mv | AT yongpeng theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT yongpeng theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT yongpeng theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT diqin theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT yudiwang theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT lianxue theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT yaxuanqin theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT xinxu theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT yongpeng effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT yongpeng effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT yongpeng effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT diqin effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT yudiwang effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT lianxue effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT yaxuanqin effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis AT xinxu effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis |